1-3 of 3
Kevin J. Marchbank
Close
Sort by
Journal Articles

Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

CME Clinical Trials & Observations
Vicky Brocklebank, Patrick R. Walsh, Kate Smith-Jackson, Thomas M. Hallam, Kevin J. Marchbank, Valerie Wilson, Theophile Bigirumurame, Tina Dutt, Emma K. Montgomery, Michal Malina, Edwin K. S. Wong, Sally Johnson, Neil S. Sheerin, David Kavanagh
Journal: Blood
Blood (2023) 142 (16): 1371–1386.
https://doi.org/10.1182/blood.2022018833
Published: 2023
Includes: Supplemental data
Journal Articles

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Nigel J. Francis, Bairbre McNicholas, Atif Awan, Mary Waldron, Donal Reddan, Denise Sadlier, David Kavanagh, Lisa Strain, Kevin J. Marchbank, Claire L. Harris, Timothy H. J. Goodship
Journal: Blood
Blood (2012) 119 (2): 591–601.
https://doi.org/10.1182/blood-2011-03-339903
Published: 2012
Includes: Supplemental data
Journal Articles

Association of factor H autoantibodies with deletions of CFHR1 , CFHR3 , CFHR4 , and with mutations in CFH , CFI , CD46 , and C3 in patients with atypical hemolytic uremic syndrome

Iain Moore, Lisa Strain, Isabel Pappworth, David Kavanagh, Paul N. Barlow, Andrew P. Herbert, Christoph Q. Schmidt, Scott J. Staniforth, Lucy V. Holmes, Roy Ward, Lynn Morgan, Timothy H. J. Goodship, Kevin J. Marchbank
Journal: Blood
Blood (2010) 115 (2): 379–387.
https://doi.org/10.1182/blood-2009-05-221549
Published: 2010